Choosing a Gliptin
The treatment of type 2 diabetes mellitus (T2DM) has included the use of metformin and sulfonylurea (SU) as first-line anti-diabetic therapies world over since years. This remains, despite the knowledge that the combination results in a progressive decline in [beta]-cell function and by 3 years up t...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2011-01-01
|
| Series: | Indian Journal of Endocrinology and Metabolism |
| Subjects: | |
| Online Access: | http://www.ijem.in/article.asp?issn=2230-8210;year=2011;volume=15;issue=4;spage=298;epage=308;aulast=Gupta |
| _version_ | 1818585545728589824 |
|---|---|
| author | Vishal Gupta Sanjay Kalra |
| author_facet | Vishal Gupta Sanjay Kalra |
| author_sort | Vishal Gupta |
| collection | DOAJ |
| description | The treatment of type 2 diabetes mellitus (T2DM) has included the use of metformin and sulfonylurea (SU) as first-line anti-diabetic therapies world over since years. This remains, despite the knowledge that the combination results in a progressive decline in [beta]-cell function and by 3 years up to 50% of diabetic patients can require an additional pharmacological agent to maintain the glycosylated hemoglobin (HbA1c) <7.0% (UKPDS). Gliptins represent a novel class of agents that improve beta cell health and suppress glucagon, resulting in improved post-prandial and fasting hyperglycemia. They function by augmenting the incretin system (GLP-1 and GIP) preventing their metabolism by dipeptidyl peptidase-4 (DPP-4). Not only are they efficacious but also safe (weight neutral) and do not cause significant hypoglycemia, making it a unique class of drugs. This review focuses on gliptins (sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin) discussing pharmacokinetics, pharmacodynamics, efficacy, and safety. |
| first_indexed | 2024-12-16T08:38:47Z |
| format | Article |
| id | doaj.art-68ac81619b8e4ce7aa663a867c8a93a2 |
| institution | Directory Open Access Journal |
| issn | 2230-8210 2230-9500 |
| language | English |
| last_indexed | 2024-12-16T08:38:47Z |
| publishDate | 2011-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Endocrinology and Metabolism |
| spelling | doaj.art-68ac81619b8e4ce7aa663a867c8a93a22022-12-21T22:37:43ZengWolters Kluwer Medknow PublicationsIndian Journal of Endocrinology and Metabolism2230-82102230-95002011-01-0115429830810.4103/2230-8210.85583Choosing a GliptinVishal GuptaSanjay KalraThe treatment of type 2 diabetes mellitus (T2DM) has included the use of metformin and sulfonylurea (SU) as first-line anti-diabetic therapies world over since years. This remains, despite the knowledge that the combination results in a progressive decline in [beta]-cell function and by 3 years up to 50% of diabetic patients can require an additional pharmacological agent to maintain the glycosylated hemoglobin (HbA1c) <7.0% (UKPDS). Gliptins represent a novel class of agents that improve beta cell health and suppress glucagon, resulting in improved post-prandial and fasting hyperglycemia. They function by augmenting the incretin system (GLP-1 and GIP) preventing their metabolism by dipeptidyl peptidase-4 (DPP-4). Not only are they efficacious but also safe (weight neutral) and do not cause significant hypoglycemia, making it a unique class of drugs. This review focuses on gliptins (sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin) discussing pharmacokinetics, pharmacodynamics, efficacy, and safety.http://www.ijem.in/article.asp?issn=2230-8210;year=2011;volume=15;issue=4;spage=298;epage=308;aulast=GuptaDiabetes mellitusdipeptidyl-dipeptidasedipeptidyl peptidase-4-inhibitorsgliptinsGLPincretins |
| spellingShingle | Vishal Gupta Sanjay Kalra Choosing a Gliptin Indian Journal of Endocrinology and Metabolism Diabetes mellitus dipeptidyl-dipeptidase dipeptidyl peptidase-4-inhibitors gliptins GLP incretins |
| title | Choosing a Gliptin |
| title_full | Choosing a Gliptin |
| title_fullStr | Choosing a Gliptin |
| title_full_unstemmed | Choosing a Gliptin |
| title_short | Choosing a Gliptin |
| title_sort | choosing a gliptin |
| topic | Diabetes mellitus dipeptidyl-dipeptidase dipeptidyl peptidase-4-inhibitors gliptins GLP incretins |
| url | http://www.ijem.in/article.asp?issn=2230-8210;year=2011;volume=15;issue=4;spage=298;epage=308;aulast=Gupta |
| work_keys_str_mv | AT vishalgupta choosingagliptin AT sanjaykalra choosingagliptin |